The effect of Renal Denervation on Renal Flow in Humans - Renal Flow after pRD

niversitair Medisch Centrum Utrecht0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•1. Individual is accepted for treatment with renal denervation as standard therapy for resistant hypertension.
•2. Individual is >=18 years of age.
•3.Individual agrees to have all study procedures performed, and is competent and willing to provide written informed consent to participate in this clinical study.

•1.Individual is excluded from treatment with pRDN .
•2.Individual has an estimated glomerular filtration rate (eGFR) of <30mL/min/1.73m2, using the MDRD calculation.
•3.Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months of the screening visit, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques.
•4.Individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, haemophilia or significant anaemia).
•5.Individual is pregnant, nursing or planning to be pregnant.
•6.Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.

发起方

niversitair Medisch Centrum Utrecht